• 1
    Haylen BT, de Ridder D, Freeman RM et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29: 420
  • 2
    Milsom I. Epidemiology of urinary (UI) and faecal (FI) incontinence and pelvic organ prolapse (POP). In AbramsP, CardozoL, KhouryS, WeinA eds, Incontinence, 4th edn. Comm 1. Paris: Health Publications Ltd. London, Editions 21, 2009: 35112
  • 3
    Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. The economic impact of overactive bladder in six Western countries. BJU Int 2008; 103: 2029
  • 4
    Steers WD. Overactive bladder (OAB): what we thought we knew and what we know today. Eur Urol Suppl 2002; 1: 310
  • 5
    Milsom I, Irwin DE. A cross-sectional population-based multinational study of the prevalence of overactive bladder and lower urinary tract symptoms: results from the EPIC study. Eur Urol Suppl 2007; 6: 49
  • 6
    Dmochowski RR, Staskin D. Overactive bladder in men: special considerations for evaluation and management. Urology 2002; 5 (Suppl. 1): 5662
  • 7
    Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008; 101: 138895
  • 8
    Epstein LB, Goldberg RP. The overactive bladder and quality of life. Int J Fertil Womens Med 2005; 50: 306
  • 9
    Wein RR, Rackley RR. Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol 2006; 175: S510
  • 10
    NICE. Urinary Incontinence: The Management of Urinary Incontinence in Women. NICE guideline. October 2006
  • 11
    Khullar V, Chapple C, Gabriel Z, Dooley JA. The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 2006; 68: 3848
  • 12
    Chapple CR, Khullar V, Gabriel Z et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 55: 54362
  • 13
    Ryan M. Using discrete choice experiments in healthcare. BMJ 2004; 328: 3601
  • 14
    Gerrard K. Benefit valuation in health economics. In Ian JBateman ed. Using Discrete Choice Experiments to Value Health and Health Care, Dordrecht: Springer, 2008: 1346
  • 15
    Ryan M. Using discrete choice experiments to value healthcare programmes: current practice and future research reflections. Appl Health Econ Health Policy 2003; 2: 5564
  • 16
    Hall J, Fiebig D, King M, Hossain I, Louviere JJ. What influences participation in genetic carrier testing? Results from a discrete choice experiment. J Health Econ 2006; 25: 52037
  • 17
    Scott A, Watson MS, Ross S. Eliciting preferences of the community for out of hours care provided by general practitioners: a stated preference discrete choice experiment. Soc Sci Med 2003; 56: 80314
  • 18
    Watson V, Ryan M, Barnett G, Ellis B, Emberton M, Brown C. Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2004; 172: 232125
  • 19
    Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology 2004; 64: 26
  • 20
    Miller J, Hoffman E. The causes and consequences of overactive bladder. J Womens Health 2006; 15: 25159
  • 21
    Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760
  • 22
    Willis GB. Cognitive Interviewing. London: Sage Publications, Ltd, 2005
  • 23
    Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. Urology 2010; 75: 491500
  • 24
    Shah D, Badlani G. Treatment of overactive bladder and incontinence in the elderly. Rev Urol 2002; 4: S3843
  • 25
    Weinstein ND. What does it mean to understand a risk? Evaluating risk comprehension. J Natl Cancer Inst 1999; 25: 1520